Company Overview
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +267.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 267.60% |
Stock Price Performance
| 1 Year: | -4.70% |
| 6 Months: | +62.18% |
| 3 Months: | +58.14% |
| 1 Month: | +4.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACOG Alpha Cognition Inc. PHARMA | 9.52 | -9.92 | $207.33M | 0.00% | -31.98% | -49.53% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 2.93M | 1.66M | 2.84M | 2.79M | 3.53M |
| Cost of Revenue | - | - | - | - | - | - | 836.54K | 534.10K | 628.06K | 252.25K | 271.78K |
| Gross Profit | - | - | - | - | - | - | 2.09M | 1.12M | 2.21M | 2.54M | 3.26M |
| Operating Expenses | - | - | - | - | - | - | 5.43M | 6.86M | 7.51M | 10.47M | 11.36M |
| Operating Income | -2.73M | -2.77M | -4.41M | -2.42M | -2.49M | - | -3.33M | -5.74M | -5.30M | -7.93M | -8.10M |
| EBITDA | - | - | - | - | - | - | -3.33M | -5.73M | -5.29M | -7.88M | -8.07M |
| Interest Expense | - | - | - | - | - | 20.39K | 13.70K | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -1.73M | -10.49M | -1.32M | -6.86M | -6.48M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.82M | -3.27M | -5.00M | -2.12M | -1.86M | - | -1.73M | -10.49M | -1.32M | -6.86M | -6.48M |
| Diluted EPS | -0.03 | -0.84 | -0.87 | -0.35 | -0.31 | - | -0.11 | -0.65 | -0.30 | - | -0.32 |
| R&D Expense | 1.25M | 1.43M | 916.72K | 967.20K | 996.03K | - | 400.42K | 317.12K | 573.59K | - | 1.10M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 10.22M |
| Cost of Revenue | - | - | - | 0 | 1.92M |
| Gross Profit | - | - | - | 0 | 8.30M |
| Operating Expenses | - | 13.47M | 9.62M | 11.55M | 30.88M |
| Operating Income | - | -13.47M | -9.62M | -11.55M | -22.58M |
| EBITDA | - | -11.85M | -13.60M | -11.47M | -22.52M |
| Interest Expense | 528.16K | 172.88K | 77.29K | 185.78K | - |
| Pretax Income | - | -12.11M | -13.76M | -14.79M | -20.67M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -12.11M | -13.76M | -14.79M | -20.67M |
| Diluted EPS | - | -4.50 | -3.84 | -2.04 | -1.17 |
| R&D Expense | - | - | 4.88M | 3.92M | 1.87M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 2.95M | 2.45M | 50.74M | 79.73M |
| Current Assets | - | 2.33M | 1.92M | 50.25M | 79.01M |
| Cash & Equivalents | - | 2.08M | 1.40M | 48.55M | 66.05M |
| Inventory | - | - | 0 | 615.13K | 5.12M |
| Receivables | - | - | - | 0 | 4.24M |
| Total Liabilities | - | 4.27M | 7.16M | 11.64M | 17.20M |
| Current Liabilities | - | 4.06M | 2.62M | 3.35M | 9.13M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | 1.08M | 1.21M | 1.21M | 911.46K | - |
| Total Equity | - | -1.32M | -4.70M | 39.09M | 62.53M |
| Shares Outstanding | - | 2.72M | 4.73M | 16.02M | 21.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.24M | -8.80M | -7.76M | -20.38M |
| Investing Cash Flow | - | -4.88K | 0 | -26.70K | -293.49K |
| Financing Cash Flow | - | 24.79K | 8.23M | 54.85M | 38.21M |
| Capital Expenditure | -63.67K | -4.88K | - | -26.70K | -293.49K |
| Free Cash Flow | - | -9.25M | -8.80M | -7.78M | -20.67M |
| Net Change in Cash | - | -9.22M | -569.55K | 47.07M | 17.54M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 81.3% |
| Operating Margin % | - | - | - | - | -220.9% |
| Net Margin % | - | - | - | - | -202.2% |
| ROE % | - | 917.7% | 292.6% | -37.8% | -33.1% |
| ROCE % | - | 1,217.6% | 5,870.9% | -24.4% | -32.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 13.30% | 2.90M | $25.57M |
| 2 | Solas Capital Management, LLC | 8.84% | 1.92M | $16.99M |
| 3 | AWM Investment Company, Inc. | 7.68% | 1.67M | $14.77M |
| 4 | Cable Car Capital, LP | 6.35% | 1.38M | $12.21M |
| 5 | Ikarian Capital, LLC | 3.84% | 836.26K | $7.38M |
| 6 | Sphera Funds Management Ltd. | 2.51% | 545.82K | $4.82M |
| 7 | Alyeska Investment Group, L.p. | 1.68% | 365.00K | $3.22M |
| 8 | Aristides Capital, LLC | 1.00% | 218.51K | $1.93M |
| 9 | Boothbay Fund Management, LLC | 0.87% | 189.15K | $1.67M |
| 10 | Cantor Fitzgerald, L.P. | 0.50% | 108.92K | $961.75K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACOG
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia & GRAPEVINE, Texas, September 01, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerati…
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZUNVEYL launch setup, …
Alpha Cognition (ACOG) Stock Fair Value Rises After Zunveyl Analyst Optimism
The fair value price target for Alpha Cognition has shifted from about US$14.67 to US$16.75, which places the stock in a higher valuation range than before. Recent analyst commentary links this move to expectations around Zunveyl, including…
Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript
ZUNVEYL revenue surged 71% sequentially as repeat prescriber rates hit 76%.
Alpha Cognition Q2 Earnings Call Highlights
Alpha Cognition (NASDAQ:ACOG) reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growin…
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ACOG — Frequently Asked Questions
What is the current share price of Alpha Cognition Inc. (ACOG)?
As of 2026-09-19 21:16 PDT, Alpha Cognition Inc. (ACOG) trades at $9.52 on NasdaqCM. Its 52-week range is $4.50 to $9.99.
What is the market capitalisation of ACOG?
Alpha Cognition Inc. (ACOG) has a market capitalisation of $207.33M on NasdaqCM.
What is the P/E ratio of ACOG?
ACOG trades at a trailing price-to-earnings (P/E) ratio of -9.92. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.75.
What is the return on equity (ROE) of ACOG?
ACOG has a return on equity (ROE) of -49.53%. Its return on capital employed (ROCE) is -31.98%.
Is ACOG a good stock to buy?
This page provides a data-driven analysis of Alpha Cognition Inc. (ACOG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.